nach oben

Erschienen in:

01.09.2008

Differential Expression of Dysadherin in Papillary Thyroid Carcinoma and Microcarcinoma: Correlation with E-cadherin

verfasst von: Anna Batistatou, Konstantinos Charalabopoulos, Yukihiro Nakanishi, Constantine Vagianos, Setsuo Hirohashi, Niki J. Agnantis, Chrissoula D. Scopa

Erschienen in: Endocrine Pathology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Dysadherin is a novel glycoprotein, with an anti-cell–cell adhesion function. The aim of the present study was to examine the expression of dysadherin in thyroid papillary microcarcinoma (PMC), to associate it with the expression of E-cadherin and to investigate whether there are differences with papillary carcinoma (PC). A statistically significant difference in dysadherin and E-cadherin expression between PC and PMC and a negative correlation between E-cadherin and dysadherin expression regardless of tumor size were noted. Based on these findings it is hypothesized that retained cell–cell adhesion, through maintenance of the E-cadherin adhesion system, in PMC prevents neoplastic cells from dissociating easily from each other and metastasizing. Increased dysadherin expression is possibly one of the post-transcriptional mechanisms responsible for E-cadherin downregulation in thyroid papillary neoplasia.

Machens A, Holzhausen H-J, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 203:2269–73, 2005. doi:10.1002/cncr.21055.CrossRef

Scopa CD. Histopathology of thyroid tumors. An overview. Hormones 3:100–10, 2004.PubMed

Scopa CD, Petrohilos J, Spiliotis J, Melachrinou M. Autopsy findings in clinically normal thyroids. A study in southwestern Greek population. Int J Surg Pathol 1:25–32, 1993. doi:10.1177/106689699300100104.CrossRef

Baloch ZW, Livolsi VA. Microcarcinoma of the thyroid. Adv Anat Pathol 13:69–75, 2006. doi:10.1097/01.pap.0000213006.10362.17.PubMedCrossRef

Piersanti M, Ezzat S, Asa SL. Controversies in papillary microcarcinoma of the thyroid. Endocr Pathol 14:183–91, 2003.PubMedCrossRef

Lak AK, Lo CY, Lam KS. Papillary carcinoma of thyroid: a 30-yr clinicopathological review of the histological variants. Endocr Pathol 16:323–30, 2005. doi:10.1385/EP:16:4:323.CrossRef

Rosai J, LiVolsi VA, Sobrinho-Simoes M, Williams ED. Renaming papillary microcarcinoma of the thyroid gland: the Porto proposal. Int J Surg Path 11:249–51, 2003. doi:10.1177/106689690301100401.CrossRef

Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306, 2006. doi:10.1038/nrc1836.PubMedCrossRef

Tetzlaff MT, Liu A, Xu X, Master SR, Balwin DA, Tobias JW, Livolsi VA, Baloch ZN. Differential expression of miRNAs in papillary thyroid carcinoma compared in formalin fixed paraffin embedded tissues. Endocr Pathol 18:163–73, 2007. doi:10.1007/s12022-007-0023-7.PubMedCrossRef

10.

Abrosimov A, Saenko V, Meirmarov S, Nakashima M, Rogounocitch T, Shkurko O, Lushnikov E, Mitsutake N, Namba H, Yamashita S. The cytoplasmic expression of MUC1 in papillary thyroid carcinoma of different histological variants and its correlation with cyclin D1 overexpression. Endocr Pathol 18:68–75, 2007. doi:10.1007/s12022-007-0012-x.PubMedCrossRef

11.

Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251:1451–5, 1991. doi:10.1126/science.2006419.PubMedCrossRef

12.

Charalabopoulos K, Binolis J, Karkabounas S. Adhesion molecules in carcinogenesis. Exp Oncol 24:249–57, 2002.

13.

Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci 94:575–81, 2003. doi:10.1111/j.1349-7006.2003.tb01485.x.PubMedCrossRef

14.

Serini G, Trusolino L, Saggiorato E, Cremona O, De Rossi M, Angeli A, Orlandi F, Marchisio PC. Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. J Natl Cancer Inst 88:442–9, 1996. doi:10.1093/jnci/88.7.442.PubMedCrossRef

15.

von Wasielewski R, Rhein A, Werner M, Scheumann GF, Dralle H, Pötter E, Brabant G, Georgii A. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 57:2501–7, 1997.

16.

Kapran Y, Ozbey N, Molvalilar S, Sncer E, Dizdaroglu F, Ozarmagan S. Immunohistochemical detection of E-cadherin, alpha- and beta-catenins in papillary thyroid carcinoma. J Endocrinol Invest 25:578–85, 2002.PubMed

17.

Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC, Sobrinho-Simoes M. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42:580–7, 2002. doi:10.1046/j.1365-2559.2003.01642.x.CrossRef

18.

Soares P, Berx G, van Roy F, Sobrinho-Simoes M. E-cadherin gene alterations are rare events in thyroid tumors. Int J Cancer 70:32–8, 1997. doi:10.1002/(SICI)1097-0215(19970106)70:1<32::AID-IJC5>3.0.CO;2-7.PubMedCrossRef

19.

Graff JR, Greenberg VE, Herman JG, Westra WH, Boghaert ER, Ain KB, Saji M, Zeiger MA, Zimmer SG, Baylin SB. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle’s cell and poorly differentiated human thyroid carcinoma. Cancer Res 58:2063–6, 1998.PubMed

20.

Nam JS, Hirohashi S, Wakefield LM. Dysadherin: a new player in cancer progression. Cancer Lett 255:161–9, 2007. doi:10.1016/j.canlet.2007.02.018.PubMedCrossRef

21.

Fu X, Kamps MP. E2A-Pbx1 induces aberrant expression of tissue specific and developmentally regulated genes when expressed in NIH 3T3 fibroblasts. Mol Cel Biol 17:1503–12, 1991.

22.

Batistatou A, Peschos D, Tsanou H, Charalabopoulos A, Nakanishi Y, Hirohashi S, Agnantis NJ, Charalabopoulos K. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. Br J Cancer 96:1404–8, 2007.PubMed

23.

Shimada Y, Yamasaki S, Hashimoto Y, Ito T, Kawamura J, Soma T, Ino Y, Nakanishi Y, Sakamoto M, Hirohashi S, Imamura M. Clinical significance of dysadherin expression in gastric cancer patients. Clin Cancer Res 10:2818–23, 2004. doi:10.1158/1078-0432.CCR-0633-03.PubMedCrossRef

24.

Aoki S, Shimamura T, Shibata T, Nakanishi Y, Moriya Y, Sato Y, Kitajima M, Sakamoto M, Hirohashi S. Prognostic significance of dysadherin expression in advanced colorectal carcinoma. Br J Cancer 88:726–32, 2003. doi:10.1038/sj.bjc.6600778.PubMedCrossRef

25.

Batistatou A, Charalabopoulos A, Scopa CD, Nakanishi Y, Kappas A, Hirohashi S, Agnantis NJ, Charalabopoulos K. Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. Virchows Arch 448:763–7, 2006. doi:10.1007/s00428-006-0183-8.PubMedCrossRef

26.

Shimamura T, Sakamoto T, Ino Y. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to E-cadherin expression. J Clin Oncol 21:659–67, 2003. doi:10.1200/JCO.2003.06.179.PubMedCrossRef

27.

Shimada Y, Hashimoto Y, Kan T, Kawamura J, Okumura T, Soma T, Kondo K, Teratani N, Watanabe G, Ino Y, Sakamoto M, Hirohashi S, Imamura M. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology 67:73–80, 2004. doi:10.1159/000080289.PubMedCrossRef

28.

Sato H, Ino Y, Miura A, Abe Y, Sakai H, Ito K, Hirohashi S. Dysadherin: expression and clinical significance in thyroid carcinoma. J Clin Endocrinol Metabol 88:4407–12, 2003. doi:10.1210/jc.2002-021757.CrossRef

29.

Nakanishi Y, Akimoto S, Sato Y, Kanai Y, Sakamoto M, Hirohashi S. Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases. Appl Immunohistochem Mol Morphol 12:323–8, 2004. doi:10.1097/00129039-200412000-00006.PubMed

30.

Kyzas P, Stefanou D, Batistatou A, Agnantis NJ, Nakanishi Y, Hirohashi S, Charalabopoulos K. Dysadherin expression in head and neck squamous cell carcinoma: association with lymphagiogenesis and prognostic significance. Am J Surg Pathol 39:185–93, 2006. doi:10.1097/01.pas.0000178090.54147.f8.

31.

Batistatou A, Scopa CD, Ravazoula P, Nakanishi Y, Peschos D, Agnantis NJ, Hirohashi S, Charalabopoulos KA. Involvement of dysadherin and E-cadherin in the development of testicular tumors. Br J Cancer 93:1382–7, 2005. doi:10.1038/sj.bjc.6602880.PubMedCrossRef

32.

Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland JM, Suo Z. Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. Pathol Oncol Res 10:212–8, 2004.PubMedCrossRef

33.

Nishizawa A, Nakanishi Y Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A, Hanada K, Kanai Y, Hirohashi S. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma. Cancer 103:1693–700, 2005. doi:10.1002/cncr.20984.PubMedCrossRef

34.

Nam J-S, Kang M-J, Suchar A, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 66:7176–84, 2006. doi:10.1158/0008-5472.CAN-06-0825.PubMedCrossRef

35.

Khoo ML, Ezzat S, Freeman JL, Asa SL. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metabol 87:1810–3, 2002. doi:10.1210/jc.87.4.1810.CrossRef

36.

Ito Y, Yoshida H, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K, Miyauchi A. p130 expression in thyroid neoplasms: its linkage with tumor size and dedifferentiation. Cancer Lett 192:83–7, 2003. doi:10.1016/S0304-3835(02)00627-4.PubMedCrossRef

37.

Ito Y, Suzuki T, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Yamamoto T, Miyauchi A. Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid. Cancer Lett 220:237–42, 2005. doi:10.1016/j.canlet.2004.08.017.PubMedCrossRef

38.

Khoo MLC, Beasley NJP, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metabol 87:1814–8, 2002. doi:10.1210/jc.87.4.1814.CrossRef

39.

Batistatou A, Zolota V, Scopa CD. S-100 protein + dendritic cells and CD34+ dendritic interstitial cells in thyroid lesions. Endocr Pathol 13:111–5, 2002. doi:10.1385/EP:13:2:111.PubMedCrossRef

Titel: Differential Expression of Dysadherin in Papillary Thyroid Carcinoma and Microcarcinoma: Correlation with E-cadherin
verfasst von: Anna Batistatou
Konstantinos Charalabopoulos
Yukihiro Nakanishi
Constantine Vagianos
Setsuo Hirohashi
Niki J. Agnantis
Chrissoula D. Scopa
Publikationsdatum: 01.09.2008
Verlag: Humana Press Inc
Erschienen in: Endocrine Pathology / Ausgabe 3/2008
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI: https://doi.org/10.1007/s12022-008-9035-1

Springer Medizin

Differential Expression of Dysadherin in Papillary Thyroid Carcinoma and Microcarcinoma: Correlation with E-cadherin

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Diagnostic Controversies in Vascular Proliferations of the Thyroid Gland

The Genomic Revolution and Endocrine Pathology

Poorly Differentiated Thyroid Carcinoma: Diagnostic Features and Controversial Issues

Molecular Detection of PPARγ Rearrangements and Thyroid Carcinoma in Preoperative Fine-Needle Aspiration Biopsies

Metastatic Small Cell Carcinoma to the Thyroid Gland: a Pathologic and Molecular Study Demonstrating the Origin in the Urinary Bladder

True Adrenal Mesothelial Cyst in a Patient with Flank Pain and Hematuria

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie